GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2011

Lilly to Use ArGEN-X Technology for mAb R&D

  • arGEN-X and Eli Lilly have agreed to discover and develop therapeutic antibody products against targets submitted by Lilly. arGEN-X will receive license fees and research funding as well as potential milestone payments.

    arGEN-X will generate novel human mAb candidates that act on diverse functional sites on Lilly targets using using its Simple Antibody platform. Lilly will have the option to select the most promising mAb candidates to take forward into preclinical and clinical development and potential commercialization.

    The Simple Antibody technology generates antibodies that do not need in vitro affinity maturation. It is based on the discovery that the binding sites of conventional four-chain antibodies in immunized Camelids have phenomenal functional attributes and comprise sequences and structures that are effectively human. Candidates generated on the platform have the closest possible homology to human germline sequence and the ideal human constant region isotype for functional performance, according to the company.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?